Tema腫瘤學主動型ETF CANC 深 滬
等待開盤 02-10 09:30:00 美东时间
36.56
-0.020
-0.05%
華盛通- 最 高36.72
- 今 開36.72
- 成交量 2.11万股
- 最 低 36.30
- 昨 收 36.58
- 總市值 1.51亿
- 52周最高 37.51
- 市盈率 靜 --
- 換手率 0.51%
- 52周最低 20.0759
- 委 比 20.00%
- 總股本 414.00万
- 歷史最高 37.51
- 量 比 0.91
- 振 幅 1.15%
- 歷史最低 20.0759
- 每 手 1
- 風險率 4.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Stellantis Resets Business, Books $22 Bln Charge
BRIEF-Stellantis Resets Business, Books $22 Bln Charge Feb 6 (Reuters) - Stellantis NV STLAM.MI : STELLANTIS RESETS ITS BUSINESS TO MEET CUSTOMER PREFERENCES AND TO SUPPORT PROFITABLE GROWTH ANNOUNCES €22 BILLION CHARGES FOR STRATEGIC SHIFT SUSPENDS DIVIDEND, AUTHORIZES €5 BILLION HYBRID BONDS TO I
02-06 15:12
BRIEF-Relay Therapeutics Announces Zovegalisib Granted Therapy Designation By FDA For Pik3ca-Mutant
BRIEF-Relay Therapeutics Announces Zovegalisib Granted Therapy Designation By FDA For Pik3ca-Mutant Feb 3 (Reuters) - Relay Therapeutics Inc RLAY.O : RELAY THERAPEUTICS ANNOUNCES ZOVEGALISIB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA FOR PIK3CA-MUTANT, HR+/HER2- ADVANCED BREAST CANCER Sour
02-03 21:11
BRIEF-Opdivo Plus Yervoy Reimbursed Under Ontario's Fast Program As First-Line Treatment For Advanced Liver Cancer
BRIEF-Opdivo Plus Yervoy Reimbursed Under Ontario's Fast Program As First-Line Treatment For Advanced Liver Cancer Feb 3 (Reuters) - Bristol-Myers Squibb Co BMY.N : OPDIVO® PLUS YERVOY® REIMBURSED UNDER ONTARIO'S FAST PROGRAM AS FIRST-LINE TREATMENT FOR ADVANCED LIVER CANCER Source text: ID:nCNWYmPS
02-03 21:08
BRIEF-IHH Healthcare Made A Strategic Investment In U.S.-Based TibaRay
BRIEF-IHH Healthcare Made A Strategic Investment In U.S.-Based TibaRay Jan 29 (Reuters) - IHH Healthcare Bhd IHHH.KL : MADE A STRATEGIC INVESTMENT IN U.S.-BASED TIBARAY INVESTMENT IN NEXT-GENERATION RADIOTHERAPY AIMS TO MAKE CANCER TREATMENT MORE EFFICIENT, OTHERS Further company coverage: IHHH.KL
01-29 14:48
BRIEF-Rhythm Biosciences Secures Strategic Us Partnership With Cancer IQ
BRIEF-Rhythm Biosciences Secures Strategic Us Partnership With Cancer IQ Jan 28 (Reuters) - Rhythm Biosciences Ltd RHY.AX : SECURES STRATEGIC US PARTNERSHIP WITH CANCER IQ Further company coverage: RHY.AX (( Reuters.Briefs@thomsonreuters.com ;))
01-28 09:37
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results
BRIEF-New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results Jan 21 (Reuters) - Gilead Sciences Inc GILD.O : NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE
01-22 06:18
BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers Jan 21 (Reuters) - Actuate Therapeutics Inc ACTU.O : ACTUATE THERAPEUTICS ANNOUNCES PLANS TO EXPAND CLINICAL PIPELINE, ADVANCING ELRAGLUSIB TABL
01-21 21:46
Tema Oncology ETF declares $0.0196 dividend
Tema Oncology ETF (CANC) declares $0.0196/share annual dividend. Payable Dec. 11; for shareholders of record Dec. 10; ex-div Dec. 10. See CANC Dividend Scorecard, Yield Chart, & Dividend Growth. More ...
2025-12-10 22:30
BRIEF-International Unions Trading Cancels Offering Of Shares On Parallel Market - Adviser
Jan 30 (Reuters) - YAQEEN CAPITAL: INTERNATIONAL UNIONS TRADING CANCELS OFFERING OF SHARES ON PARALLEL MARKET - ADVISER ((Reuters.Briefs@thomsonreuters.com;))
2025-01-30 13:42
